B. Riley Estimates Agenus' FY2025 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN - Free Report) - Investment analysts at B. Riley upped their FY2025 earnings per share estimates for shares of Agenus in a report released on Thursday, May 15th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings of $6.14 per share for the year, up from their previous estimate of ($3.44). B. Riley currently has a "Buy" rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share. B. Riley also issued estimates for Agenus' FY2026 earnings at ($4.88) EPS.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million.

AGEN has been the topic of several other reports. Wall Street Zen upgraded Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday. Robert W. Baird boosted their price target on Agenus from $3.00 to $4.00 and gave the company a "neutral" rating in a research note on Tuesday, May 13th. Finally, HC Wainwright restated a "neutral" rating on shares of Agenus in a research note on Tuesday, May 13th. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $9.00.

Agenus Price Performance

Shares of NASDAQ AGEN traded up $0.03 during trading hours on Monday, hitting $3.82. 422,744 shares of the company's stock were exchanged, compared to its average volume of 590,940. Agenus has a 1-year low of $1.38 and a 1-year high of $19.69. The stock has a market capitalization of $104.73 million, a price-to-earnings ratio of -0.34 and a beta of 1.48. The company's 50-day moving average price is $2.44 and its 200-day moving average price is $2.88.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently bought and sold shares of AGEN. Barclays PLC lifted its stake in Agenus by 295.3% in the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company's stock valued at $152,000 after purchasing an additional 20,777 shares during the last quarter. Apollon Wealth Management LLC acquired a new stake in Agenus in the 4th quarter valued at about $55,000. Virtu Financial LLC acquired a new stake in Agenus in the 4th quarter valued at about $51,000. Bank of Montreal Can acquired a new stake in Agenus in the 4th quarter valued at about $69,000. Finally, Gilead Sciences Inc. acquired a new stake in Agenus in the 4th quarter valued at about $635,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.